Summit Therapeutics
Clinical trials sponsored by Summit Therapeutics, explained in plain language.
-
New hope for advanced colon cancer: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 study tests whether a new drug called ivonescimab, combined with standard chemotherapy (FOLFOX), works better than the current standard treatment (bevacizumab plus FOLFOX) for people with metastatic colorectal cancer that has spread. About 600 adults who have not had…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy combo aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new immunotherapy drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. The st…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New lung cancer drug ivonescimab takes on pembrolizumab in major trial
Disease control Recruiting nowThis phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC